SEC FORM 3

Please wait

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Grujic Alan

(Last)

(First)

(Middle)

5835 PEACHTREE CORNERS EAST, SUITE B

(Street)

NORCROSS

30092

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/07/2023

3. Issuer Name and Ticker or Trading Symbol
GUIDED THERAPEUTICS INC [ GTHP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,388,909	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series E Preferred Stock	08/21/2020	⁽²⁾	Common Stock	50	$4,000	D
Warrants to Purchase Common Stock	09/01/2022	09/01/2026	Common Stock	500,000	$0.5	D
Warrants to Purchase Common Stock	09/01/2022	09/01/2026	Common Stock	500,000	$0.65	D
Warrants to Purchase Common Stock	09/02/2022	09/02/2023	Common stock	800,000	$0.5	D
Stock Option (right to buy)	⁽¹⁾	03/06/2033	Common Stock	100,000	$0.27	D

Explanation of Responses:

1. One-fourth of the shares subject to the award vested on March 7, 2023; the remaining shares will vest monthly, starting 90 days from the grant date, subject to the reporting person's continued service on each such date, until the award is fully vested on March 7, 2026.

2. These securities consist of Series E Convertible Preferred Stock ("Series E Preferred") of the Issuer that are presently convertible on a 1-for-4,000 basis into Common Stock without payment or further consideration. The Series E Preferred shares are convertible at any time for a period of five years after issuance. The Series E Preferred have no expiration date.

Remarks:

	/s/ Alan Grujic	06/20/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.